Phase IV study of afatinib as second-line therapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring common epidermal growth factor receptor (EGFR) mutations (Del19 and/or L858R)

Thongprasert, Sumitra; ...; Jovanovic, D; ...; Petrovic, M; ...; Radosavljevic, Davorin Z; Perin, Branislav M; ...; (broj, koautora 19)

Rezultati

eNauka > Rezultati > Phase IV study of afatinib as second-line therapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring common epidermal growth factor receptor (EGFR) mutations (Del19 and/or L858R)

Naziv:	Phase IV study of afatinib as second-line therapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring common epidermal growth factor receptor (EGFR) mutations (Del19 and/or L858R)
Autori:	Thongprasert, Sumitra; ...; Jovanovic, D; ...; Petrovic, M; ...; Radosavljevic, Davorin Z; Perin, Branislav M; ...; (broj, koautora 19)
Godina:	2015
Publikacija:	ANNALS OF ONCOLOGY
ISSN:	0923-7534 Annals of Oncology Pretraži identifikator
Tip rezultata:	Konferencijski rad
Kolacija:	vol. 26 str. 146-146
WoS-ID:	000367158700476
URI:	https://enauka.gov.rs/handle/123456789/808695
Izvor metapodataka:	(Preuzeto iz Nasi u WoS)
M-kategorija:	Mp kategorija će biti prikazana naknadno.

Pronađi DOI

Pronalaženje DOI u servisu CrossRef-u na osnovu meta-podataka u zapisu. Prikazaće se DOI (i metapodaci) čiji se podaci najviše poklapaju. OPREZ - to ne mora biti ta publikacija.

Google Scholar^TM

Rezultati na eNauka su zaštićeni autorskim pravima i sva prava su zadržana, osim ako nije drugačije naznačeno.